Francisco Hermida-Prado

14PUBLICATIONS
102CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Nov 05, 2025
CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer.

María Otero-Rosales, Miguel Álvarez-González, Irene Pazos

|Aug 22, 2025
Tamoxifen induces PI3K activation in uterine cancer.

Kirsten Kübler, Agostina Nardone, Shankara Anand

|Mar 13, 2024
Combined PIK3CA and SOX2 Gene Amplification Predicts Laryngeal Cancer Risk beyond Histopathological Grading.

Irene Montoro-Jiménez, Rocío Granda-Díaz, Sofía T Menéndez

|Feb 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.

Cristina Guarducci, Agostina Nardone, Douglas Russo

|Jul 14, 2023
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.

Francisco Hermida-Prado, Yingtian Xie, Shira Sherman

|Aug 11, 2022
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.

Agostina Nardone, Xintao Qiu, Sandor Spisak

Pageof 3

Frequent Collaborators

11 joint publications

Juana María García-Pedrero

9 joint publications

Juana M García-Pedrero

5 joint publications

Eva Allonca

4 joint publications

Rinath Jeselsohn